Clinical Trials on Bronchiectasis in Hong Kong

Total 7 results

The University of Hong Kong

Recruiting

Roflumilast in Non-CF Bronchiectasis Study (2019)

Non-cystic Fibrosis Bronchiectasis

Hong Kong
The University of Hong Kong

Completed

Roflumilast in Non-CF Bronchiectasis Study

Non-cystic Fibrosis Bronchiectasis

Hong Kong
Chinese University of Hong Kong

Recruiting

Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations

Bronchiectasis Adult

Hong Kong
Chinese University of Hong Kong

Recruiting

A Prospective Study of Factors Related to Exacerbation and Mortality of Non-cystic Fibrosis Bronchiectasis in Hong Kong

Bronchiectasis Adult

Hong Kong
Pamela Youde Nethersole Eastern Hospital

Recruiting

Microbiology and Treatment Outcome of Acute Exacerbation of Bronchiectasis in Hong Kong

Bronchiectasis

Hong Kong
Novartis Pharmaceuticals
Innovative Medicines Initiative

Terminated

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis

Bronchiectasis

Germany, Spain, United Kingdom, China
Bayer
Novartis

Completed

Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (RESPIRE 2)

Bronchiectasis

China, Hong Kong, Germany, Philippines, Russian Federation, United States, Australia, Austria, Czechia, Taiwan, Brazil, Korea, Republic of, Netherlands, Thailand, Latvia, Romania, Turkey, Serbia, Portugal, Bulgaria, Slovakia, Poland, Argenti... and more

3

Subscribe